Your Worksheet is Ready
CBSE - Class 12 Biology Biotechnology and Its Applications Worksheet
Worksheet Answers
Solution:
Oil in seeds primarily consists of triacylglycerols (TAGs). The biosynthetic pathway involves the conversion of acetyl-CoA into fatty acids within the plastids, which are then exported to the endoplasmic reticulum. Here, glycerol-3-phosphate acyltransferase (GPAT) and other enzymes catalyze the esterification of fatty acids onto a glycerol backbone [Per the Kennedy Pathway for TAG biosynthesis].
To eliminate or reduce oil content, we target the metabolic bottlenecks or the regulatory enzymes responsible for lipid deposition. The following strategy utilizes RNA interference (RNAi) or CRISPR/Cas9-mediated gene knockout.
If the goal is to remove oil *post-harvest* using rDNA technology (metabolic engineering), we convert the metabolic flux away from lipids toward alternative metabolites (e.g., starch or protein).
| Step | Process Description | Scientific Justification |
|---|---|---|
| 1. Genetic Silencing | Use siRNA to silence DGAT enzymes. | Prevents assembly of glycerol to fatty acids. |
| 2. Pathway Shunting | Upregulate ADP-glucose pyrophosphorylase. | Redirects carbon flux toward starch storage. |
| 3. Screening | Use GC-MS analysis of T1 generation seeds. | Quantifies fatty acid reduction per mg of seed weight. |
By implementing RNA interference against key enzymes like DGAT1 or Oleosin (structural proteins of oil bodies), the seed’s metabolic machinery is instructed to discontinue the storage of triacylglycerols. Instead, the carbon skeletons (previously destined for hydrocarbons) are diverted to carbohydrate biosynthesis. This renders the seed "oil-free" at the biochemical level, fulfilling the requirement through genetic modification rather than mechanical extraction.
Final Solution: The most effective method is to employ RNA interference (RNAi) to knock down the expression of the DGAT (diacylglycerol acyltransferase) gene, thereby inhibiting the terminal step of triacylglycerol (oil) synthesis and redirecting the metabolic flux toward starch or protein production.
Solution:
Gene therapy is a highly advanced clinical and biotechnological intervention comprising a collection of methods that allow for the correction of a genetic defect diagnosed in a child or an embryo. The fundamental principle revolves around the therapeutic delivery of functional nucleic acid polymers (genes) into a patient's cells to treat disease.
[By the principles of Molecular Genetics], this is achieved by inserting a normal, wild-type gene into the individual's cells and tissues to compensate for the non-functional, mutated, or deleted gene, thereby restoring the normal cellular phenotype and biochemical function.
Adenosine Deaminase (ADA) deficiency is a rare, autosomal recessive metabolic disorder that severely damages the immune system, resulting in Severe Combined Immunodeficiency (SCID).
Before the advent of gene therapy, ADA deficiency was primarily managed through two conventional approaches, both of which possess significant limitations:
| Treatment Modality | Mechanism | Limitations |
|---|---|---|
| Bone Marrow Transplantation | Replacement of defective hematopoietic stem cells with healthy ones from a matching donor. | Finding a perfect HLA-matched donor is extremely difficult. Risk of Graft-Versus-Host Disease (GVHD). |
| Enzyme Replacement Therapy (ERT) | Intravenous injection of functional, PEGylated bovine ADA enzyme. | Not entirely curative. Requires lifelong, expensive periodic injections. |
[Because neither of these methods completely cures the underlying genetic defect within the patient's own cellular lineage, gene therapy emerged as a definitive therapeutic pathway.]
The first clinical gene therapy was administered in 1990 to a 4-year-old girl suffering from ADA deficiency. The protocol involves an ex vivo (outside the body) gene transfer strategy:
While highly effective, the standard ex vivo lymphocyte gene therapy is not entirely curative.
The Limitation: Lymphocytes are not immortal (they have a finite lifespan). Therefore, the patient requires periodic infusions of the genetically engineered lymphocytes to maintain sufficient ADA enzyme levels.
The Permanent Cure: To achieve a permanent cure, the therapeutic intervention must target self-renewing cells. If the functional $ADA$ gene isolated from bone marrow cells is introduced into the cells at the early embryonic stages (or into hematopoietic stem cells), the integrated gene is passed on to all descendent cells indefinitely, providing a permanent and lifelong cure for ADA deficiency.
Final Solution: Gene therapy is the biotechnological insertion of a functional gene into a patient's cells to correct a genetic defect. Using ADA deficiency as the classic model, it involves extracting the patient's $T\text{-lymphocytes}$, utilizing a retroviral vector to integrate a functional $ADA$ $cDNA$ into their genome, and reinfusing these transformed cells back into the patient to restore purine metabolism and immune function. A permanent cure is achieved only if this genetic modification is performed at early embryonic stages or on hematopoietic stem cells.
Solution:
In plant tissue culture, the portion of the plant most suitable for the production of virus-free plants is the meristematic tissue, specifically the shoot apical meristem.
The exclusion of viruses from the shoot apical meristem is based on the following biological mechanisms [Per principles of Plant Pathology and Tissue Culture]:
Once the meristem tip (approximately $0.1$–$0.5\ mm$ in length) is excised, it is placed onto a sterile nutrient medium (e.g., Murashige and Skoog medium) under aseptic conditions [By Totipotency Principle].
| Feature | Description |
|---|---|
| Technique | Meristem-tip culture / Micropropagation |
| Outcome | Virus-free plantlet |
| Application | Commonly used for bananas, sugarcane, and potatoes |
Final Solution: The shoot apical meristem is the best suited part because it is typically free from viral infection due to the absence of vascular connections and the high rate of cell division which outpaces viral replication. Through the technique of meristem-tip culture, an entire virus-free plant can be regenerated from this small, pathogen-free explant.
Solution:
Proteins and peptides, when ingested orally, are inherently unstable in the gastrointestinal (GI) tract due to the acidic environment of the stomach and the presence of proteolytic enzymes (proteases). To render a protein pharmaceutical orally active, the engineering process involves specific drug delivery strategies to bypass or neutralize these barriers [Per Pharmacokinetic Principles of Oral Protein Delivery].
The fundamental problem, known as the "Oral Bioavailability Barrier," involves the following variables:
| Barrier Type | Description |
|---|---|
| Chemical | Stomach acidity ($pH$ 1.5–3.5) causes rapid denaturation of the tertiary protein structure. |
| Enzymatic | Pepsin, trypsin, and chymotrypsin cleave the peptide bonds, reducing proteins to individual amino acids before systemic absorption occurs. |
| Physical | Large molecular weight of proteins inhibits passage through the intestinal mucosal layer and the lipid bilayer of enterocytes [Fick’s Law of Diffusion limitations]. |
The pharmaceutical challenge is to ensure the protein reaches the systemic circulation intact. Even with protective coatings, the mucosal barrier and the high specificity of the hepatic first-pass metabolism often limit the absolute bioavailability of oral protein drugs to less than $1\%$, necessitating dose-optimization strategies that currently remain at the forefront of clinical biotechnology [Per Bioavailability Constants in Oral Delivery].
Final Solution: The development of orally active protein pharmaceuticals relies on protective encapsulation or the use of permeation enhancers. The major problem encountered is the high susceptibility of proteins to enzymatic hydrolysis in the gastrointestinal tract and their low permeability across the intestinal epithelium due to their large molecular size and hydrophilic nature.
Solution:
In plant tissue culture (micropropagation), an explant (any excised part of a plant, such as a shoot apex, leaf piece, or nodal segment) is grown in vitro under strict aseptic conditions. Because the explant is isolated from the parent plant and may not initially be fully autotrophic (capable of adequate photosynthesis), it requires an artificial, highly optimized nutrient medium to survive, undergo cell division (callus formation), and differentiate into a complete plantlet. The most widely used standard is the Murashige and Skoog (MS) medium.
The nutrient medium is formulated to mimic and optimize the chemical environment of the living plant tissue. The standard components are logically categorized into the following sequential components:
Unlike mature plants, excised explants cultured in vitro are heterotrophic or mixotrophic. They require an external supply of carbon to fuel cellular respiration and provide the carbon skeletons needed for biosynthesis.
Inorganic salts are essential for synthesizing structural components, nucleic acids, and enzymatic cofactors. These are divided based on the quantitative requirements of the plant tissue.
| Nutrient Category | Elements Provided | Physiological Role in Explant |
|---|---|---|
| Macronutrients (Required in concentrations $> 0.5 \text{ mmol/L}$) |
Nitrogen ($N$), Phosphorus ($P$), Potassium ($K$), Calcium ($Ca$), Magnesium ($Mg$), Sulfur ($S$) | Supplied as salts like $NH_4NO_3$, $KNO_3$, $KH_2PO_4$. Nitrogen is vital for amino acids and nucleic acids; Phosphorus for ATP and DNA; Magnesium is the central atom in chlorophyll; Calcium stabilizes cell walls. |
| Micronutrients (Required in trace amounts $< 0.5 \text{ mmol/L}$) |
Iron ($Fe$), Manganese ($Mn$), Zinc ($Zn$), Boron ($B$), Copper ($Cu$), Molybdenum ($Mo$), Cobalt ($Co$) | Supplied as salts like $FeSO_4$, $MnSO_4$, $ZnSO_4$. They act as essential catalytic cofactors for enzymatic reactions. Iron is usually supplied with a chelating agent (EDTA) to keep it soluble and available to the plant tissue. |
Organogenesis (the formation of roots and shoots from the explant) is strictly controlled by the concentration and ratio of specific phytohormones [Per Skoog and Miller's classical hormone ratio concept].
While plants synthesize vitamins endogenously, excised explants often synthesize them too slowly to support rapid in vitro growth.
For static culture systems, the explant must not submerge in the liquid, as this restricts oxygen availability and causes asphyxiation.
Final Solution: The medium for the in vitro propagation of an explant consists of a carbon/energy source (primarily sucrose), inorganic macronutrients (N, P, K, Ca, Mg, S) and micronutrients (Fe, Mn, Zn, B, Cu, Mo), vitamins (like thiamine), amino acids, specific plant growth regulators (auxins and cytokinins) to drive organogenesis, and agar to provide a solid mechanical support matrix.
Solution:
Golden Rice is a genetically modified (GM) variety of rice (Oryza sativa) engineered to biosynthesize $\beta$-carotene (a precursor of Vitamin A) in the edible parts of the rice grain (endosperm). Unlike conventional rice, which produces carotenoids in green tissues but lacks them in the endosperm, Golden Rice is designed to address Vitamin A deficiency (VAD) in populations where rice serves as a primary staple crop.
The biosynthetic pathway for $\beta$-carotene was introduced into the rice genome through the insertion of two specific transgenes using Agrobacterium tumefaciens-mediated transformation [Per the principles of Recombinant DNA Technology].
| Gene Source | Enzyme/Protein | Function in Pathway |
|---|---|---|
| Narcissus pseudonarcissus (Daffodil) or Zea mays (Maize) | Phytoene synthase (Psy) | Catalyzes the first committed step in carotenoid biosynthesis. |
| Pantoea ananatis (Bacterium) | Carotene desaturase (CrtI) | Completes the conversion of phytoene to lycopene. |
The development of Golden Rice signifies a shift from "first-generation" GMOs (focused on input traits like herbicide tolerance) to "second-generation" GMOs (focused on nutritional enhancement or output traits). It involves precise regulation of transgene expression under the control of endosperm-specific promoters (e.g., glutelin promoter) to ensure the carotenoids accumulate specifically within the grain [Regulatory compliance in Agricultural Biotechnology].
Final Solution: Golden Rice is a biofortified, genetically modified cultivar of Oryza sativa containing introduced transgenes (phytoene synthase and carotene desaturase) that allow the endosperm to produce $\beta$-carotene, specifically designed to combat dietary Vitamin A deficiency in populations reliant on rice as a staple food source.
Solution:
Micropropagation is an advanced biotechnological technique used for the in vitro regeneration of plants. It leverages the inherent biological property of cellular totipotency—the capacity of a single isolated plant cell or tissue (the explant) to regenerate into a complete, fully functional plant under controlled, sterile conditions. By placing an explant in a precisely formulated nutrient medium containing specific carbon sources (e.g., sucrose), inorganic salts, vitamins, amino acids, and phytohormones (such as auxins and cytokinins), researchers can induce rapid cellular division and differentiation.
The most immediate advantage of micropropagation is the exponential rate at which plants can be multiplied. Traditional agricultural propagation methods (such as seed germination or vegetative cuttings) are often limited by time, seasonality, and low yield.
A profound agricultural application of micropropagation is the recovery of completely healthy plants from pathogen-infected stock, specifically viral pathogens.
Plants produced via micropropagation are generated through strictly vegetative (mitotic) means, lacking any meiotic recombination. Consequently, the resulting progeny are genetically identical to the parent plant, collectively referred to as somaclones.
Micropropagation decouples plant production from macro-environmental variables and inherent biological bottlenecks.
The following schematic demonstrates the precise sequential transition of a biological explant through the phases of in vitro tissue culture up to successful acclimatization.
While micropropagation offers numerous benefits, its paramount significance lies in the intersection of speed, scale, and health.
Final Solution: The major advantage of producing plants by micropropagation is the rapid clonal multiplication of elite, high-yielding varieties, coupled with the ability to recover perfectly healthy, disease-free (virus-free) plants from infected stock via meristem culture, all within a compressed, season-independent timeframe.
Solution:
The bacterium Bacillus thuringiensis produces insecticidal crystal proteins, known as Cry proteins, during its sporulation phase. These proteins exist in the bacterial cell in an inactive, non-toxic form termed protoxin. The primary reasons for the lack of autotoxicity within the bacterium are delineated below:
The protein is synthesized as an inactive precursor, the protoxin, within the bacterial cytoplasm. In this state, the protein lacks the necessary configuration to interact with cellular membranes or receptors. [Per the mechanism of enzymatic regulation, the protoxin is biologically inert until specific post-translational modifications occur].
The protoxin requires a highly alkaline environment (pH > 8.5) to become soluble and to be activated. The interior of the Bacillus thuringiensis bacterium does not provide the specific alkaline conditions necessary for the conversion of the protoxin into the active toxin. [Reference: Protoxin solubility is dependent on the ionic state of amino acid residues, which is only achieved in alkaline gut environments of target larvae].
The conversion of the inactive protoxin to the active toxin (delta-endotoxin) requires proteolytic cleavage by specific midgut proteases found only in the digestive systems of susceptible insect larvae. The bacterium itself lacks the specific endopeptidases that recognize the protoxin cleavage site, thereby preventing the transformation of the protoxin into its lethal, active state.
Even if accidental activation occurred, the active toxin functions by binding to specific cadherin-like receptors located on the epithelial cells of the insect midgut. Bacillus thuringiensis cell membranes lack these specific receptors; therefore, the toxin cannot bind to or cause pore formation in the bacterial plasma membrane.
| Factor | Within Bacillus | Within Insect Gut |
|---|---|---|
| Protein Form | Inactive Protoxin | Active Toxin |
| pH Level | Neutral/Slightly Acidic | Highly Alkaline |
| Protease Activity | Absent | Present (Midgut) |
Final Solution: Crystals of Bt toxin do not kill the bacteria because the toxin is produced as an inactive protoxin and requires the specific alkaline environment and proteolytic enzymes found in the midgut of susceptible insects to become activated and bind to target receptors.
Solution:
Cry proteins (crystal proteins) are a highly specific class of proteinaceous toxic crystals (also known as $\delta$-endotoxins) that are synthesized during the stationary growth phase and sporulation of certain bacterial species. These proteins are encoded by the $cry$ genes. They are fundamentally entomocidal (insecticidal), exhibiting lethal toxicity toward specific orders of insects such as Lepidopterans (tobacco budworm, armyworm), Coleopterans (beetles), and Dipterans (flies, mosquitoes).
[Biochemical Justification]: The protein is initially synthesized as an inactive crystalline protoxin. This biological sequestration prevents the toxin from destroying the host bacterium itself.
The primary organism that produces Cry proteins is the gram-positive soil bacterium Bacillus thuringiensis (often abbreviated as Bt).
The specificity and efficacy of the Cry protein rely on a rigorous biochemical cascade within the target insect's digestive tract:
Mankind has extensively exploited the $cry$ genes of Bacillus thuringiensis through recombinant DNA technology to revolutionize agricultural pest management. The sequential methodology and outcomes are detailed below:
Benefits of Exploitation:
| Biotechnological Benefit | Scientific Impact / Rationale |
|---|---|
| Reduction in Chemical Pesticides | Transgenic "Bt crops" possess innate bio-insecticidal properties, drastically reducing the agricultural reliance on broad-spectrum, toxic synthetic chemical pesticides. |
| Ecological Specificity | Cry proteins are highly specific. They exhibit negligible toxicity to non-target organisms, including beneficial insects (e.g., pollinators like bees), mammals, and humans, ensuring ecological stability. |
| Increased Agricultural Yield | By preventing massive crop decimation caused by phytophagous insect larvae (like the bollworm destroying cotton bolls), overall crop productivity and economic viability are substantially augmented. |
Final Solution: Cry proteins are toxic, insecticidal crystal proteins produced by the bacterium Bacillus thuringiensis. Humans have exploited these proteins by isolating the associated $cry$ genes and integrating them into agricultural crops (via recombinant DNA technology) to produce pest-resistant transgenic plants such as Bt Cotton and Bt Corn.
Solution:
Transgenic bacteria are microorganisms whose genetic material (genome) has been artificially altered through the introduction of foreign DNA sequences—typically derived from another organism—using recombinant DNA technology [Per the principles of Genetic Engineering]. These organisms are engineered to express specific proteins or biochemical pathways that are not native to their original biological makeup.
The creation of transgenic bacteria involves the following sequence of molecular events:
The most significant application of transgenic bacteria is the production of recombinant human insulin. Historically, diabetic patients relied on insulin derived from porcine or bovine pancreases, which caused allergic reactions. Transgenic E. coli solved this by providing a consistent, pure human-identical protein.
| Component | Biological Role |
|---|---|
| Insulin A & B chains | Encoded by two separate DNA sequences inserted into separate E. coli cultures. |
| Host Cell | Escherichia coli provides the protein synthesis machinery (ribosomes, tRNA). |
| Post-production | The synthesized chains are extracted, purified, and joined via disulfide bonds to form active insulin. |
Transgenic bacteria serve as biological "factories." By integrating human genes into the bacterial genome, scientists utilize the rapid replication cycles and straightforward metabolic pathways of prokaryotes to produce high yields of therapeutic human proteins. This advancement is fundamental to modern clinical biotechnology [Per the principles of Biotechnology and Its Applications].
Final Solution: Transgenic bacteria are genetically modified microorganisms carrying foreign DNA. The production of human insulin via transgenic E. coli stands as the definitive clinical example, allowing for the mass production of safe, non-immunogenic medication.
Solution:
Genetically Modified (GM) crops are agricultural plants whose genomes have been specifically altered using recombinant DNA (rDNA) technology. By inserting a specific gene of interest (transgene) from a distinct organism—whether bacterial, viral, or another plant—scientists can confer novel phenotypic traits that do not naturally occur in the species. While this molecular engineering offers unprecedented agricultural optimization, it simultaneously introduces complex ecological, physiological, and socio-economic variables.
The following schematic illustrates the localized and systemic impacts of deploying transgenic plants in an agricultural ecosystem, mapping the vectors of both advantages and disadvantages.
The engineering of GM crops offers solutions to long-standing agronomic and nutritional challenges through precise molecular alterations:
Despite their agronomic benefits, GM crops introduce systemic risks to ecosystems, human biology, and the socio-economic structure of agriculture:
| Domain of Impact | Advantages of GM Crops | Disadvantages of GM Crops |
|---|---|---|
| Agricultural Economics | Higher yields per hectare; drastic reduction in the cost and labor associated with applying chemical pesticides. | High initial cost of patented seeds; prohibition on the traditional practice of seed-saving for subsequent seasons. |
| Environmental Impact | Lower accumulation of toxic agricultural chemicals (pesticides/herbicides) in the soil and local water tables. | Threat of outcrossing resulting in "superweeds"; potential toxicity to non-target insect species and broader biodiversity loss. |
| Human Health | Biofortified crops eradicate specific dietary deficiencies (e.g., Vitamin A deficiency, iron deficiency). | Expression of novel proteins can elicit unpredictable allergenic responses; risk of antibiotic resistance gene transfer. |
| Plant Physiology | Enhanced resilience to extreme osmotic/abiotic stress and delayed senescence (longer shelf life). | Potential metabolic trade-offs within the plant where the continuous expression of foreign genes limits energy available for general growth. |
Final Solution: The production of genetically modified crops represents a powerful double-edged sword in biotechnology. The principal advantages lie in agronomic optimization (pest resistance via $cry$ genes, stress tolerance) and nutritional biofortification (e.g., $\beta$-carotene in Golden Rice). Conversely, the fundamental disadvantages are rooted in ecological disruption (transgene escape leading to superweeds, harm to non-target pollinators), human health uncertainties (allergenicity), and severe socio-economic inequities driven by corporate seed monopolies. Comprehensive regulatory oversight and biosafety assessments are strictly required to balance these vectors.
Solution:
Micropropagation is a biotechnological technique involving the rapid multiplication of genetically identical plant clones through tissue culture methodologies [Per the principles of totipotency in plant biology]. By utilizing small explants (meristematic tissue, shoot tips, or nodal segments), thousands of individual plants are regenerated under controlled aseptic conditions.
The primary advantage of micropropagation over traditional propagation methods is the production of genetically uniform progeny on a massive scale, known as 'somaclones'. The following table outlines the technical superiority of this process:
| Advantage Category | Mechanism |
|---|---|
| Genetic Uniformity | Mitotic division ensures all progeny are clones of the parent plant. |
| Time Efficiency | Shortens the breeding cycle significantly by bypassing seed dormancy. |
| Pathogen Elimination | Meristem-tip culture allows for the production of virus-free plants. |
| Scaling Potential | High multiplication rate regardless of seasonal constraints. |
Final Solution: The major advantage of micropropagation is the rapid production of a large number of genetically identical, disease-free, and uniform plants (clones) within a shortened temporal framework, ensuring the commercial preservation of elite parental traits.
Solution:
In vitro propagation, or micropropagation, requires a growth medium that provides all the necessary nutrients, growth regulators, and environmental conditions that an explant (a part of a plant excised and transferred to a nutrient medium) would naturally receive from the mother plant. This medium is typically solidified with agar [Per the principles of Totipotency].
The formulation of a standard medium (e.g., Murashige and Skoog medium) consists of the following hierarchical components:
| Component Category | Constituents | Biological Function |
|---|---|---|
| Inorganic Salts | Macroelements ($N, P, K, Ca, Mg, S$) & Microelements ($Fe, Mn, Zn, B, Cu, Mo, Co$) | Essential for basic metabolic processes, osmotic balance, and structural integrity. |
| Carbon Source | Sucrose ($2-3\%$) | Acts as an energy source since explants are often heterotrophic during early stages. |
| Organic Supplements | Vitamins (Thiamine, Pyridoxine, Nicotinic acid), Amino acids (Glycine) | Act as co-factors for enzymes and essential for nitrogen metabolism. |
| Plant Growth Regulators | Auxins ($IAA, IBA, NAA$) and Cytokinins ($BAP, Kinetin$) | Regulate morphogenesis; Auxins promote root development, Cytokinins promote shoot proliferation. |
| Solidifying Agent | Agar ($0.5-1.0\%$) | Provides mechanical support; prevents the explant from drowning in the liquid medium. |
| pH Adjusters | $KOH$ or $HCl$ | Maintenance of optimal pH ($5.6-5.8$) to ensure nutrient solubility and hormonal activity. |
Final Solution: The medium used for the propagation of an explant consists of essential macro- and micro-nutrients (inorganic salts), a carbon energy source (sucrose), organic supplements (vitamins and amino acids), plant growth regulators (auxins and cytokinins), and a solidifying agent (agar), all maintained at a strictly controlled pH.
Solution:
Recombinant DNA (rDNA) technology enables the isolation, manipulation, and expression of genetic material across different biological species. To clone and express a eukaryotic gene (such as the human gene for growth hormone, hGH) into a prokaryotic host like Escherichia coli, scientists must overcome fundamental biological differences, such as the inability of bacteria to process eukaryotic introns. Therefore, the process strictly utilizes complementary DNA (cDNA) synthesized from mature mRNA, bypassing intronic sequences.
Because the human genome contains non-coding introns that E. coli cannot splice out [per the Central Dogma limitations in prokaryotes], genomic DNA is not used directly. Instead, mRNA coding for the human growth hormone is isolated from human pituitary gland cells.
A suitable vector is required to carry the human gene into the bacterial host. A plasmid (e.g., pBR322 or pUC19) is commonly selected because it possesses:
Both the human cDNA (hGH gene) and the plasmid vector are treated with the same Restriction Endonuclease (e.g., EcoRI). This enzyme recognizes specific palindromic nucleotide sequences and cleaves the phosphodiester backbone. By using the same enzyme, compatible "sticky ends" (overhanging single-stranded regions) are generated on both the human gene and the vector, which facilitates complementary base pairing.
The digested human cDNA and the cleaved plasmid vector are mixed in a reaction tube. The enzyme DNA Ligase is introduced. It acts as molecular glue, catalyzing the formation of phosphodiester bonds between the adjacent 3'-hydroxyl and 5'-phosphate groups of the sticky ends. This yields a hybrid molecule known as Recombinant DNA (rDNA).
The recombinant plasmid must be introduced into a host E. coli cell. Because DNA is a hydrophilic molecule, it cannot pass through cell membranes easily.
Not all bacteria take up the plasmid, and not all plasmids contain the human gene (some may re-circularize). The bacteria are cultured on an agar plate containing a specific antibiotic (e.g., Ampicillin).
The selected recombinant E. coli clone is grown in a large-scale continuous culture system (bioreactor) under optimal physiological conditions ($pH$, temperature, oxygen). The host's cellular machinery transcribes and translates the inserted human gene, resulting in the mass production of the human growth hormone protein. The protein is subsequently extracted, purified, and formulated for clinical use (Downstream Processing).
Final Solution: The experimental workflow involves isolating hGH mRNA, synthesizing cDNA, cleaving both the cDNA and a vector plasmid with the same restriction endonuclease, ligating them to form recombinant DNA, transforming this rDNA into competent E. coli, selecting for transformants using antibiotic resistance markers, and inducing large-scale expression of the human growth hormone inside bioreactors.
Solution:
Golden Rice is a genetically modified (transgenic) variety of rice ($Oryza$ $sativa$) developed to biosynthesize $\beta$-carotene, a precursor of Vitamin A, in the edible parts of the rice grain (the endosperm). It is termed "golden" due to the distinct yellow-orange colour imparted by the accumulation of $\beta$-carotene.
Rice is a staple food for over half of the global population. However, standard milled rice (white rice) lacks Vitamin A or its provitamin precursors. While native rice plants possess the complete biochemical pathway to synthesize $\beta$-carotene in their green, vegetative tissues (leaves), the pathway is naturally "switched off" in the endosperm due to the absence of specific enzymes. Consequently, populations relying on a predominantly rice-based diet are highly susceptible to Vitamin A Deficiency (VAD), which leads to night blindness, xerophthalmia, and severe immune system impairments.
To bypass this biological limitation, scientists Ingo Potrykus and Peter Beyer utilized recombinant DNA technology to insert the missing genes into the rice genome. [Per standard transgenic plant generation protocols], they utilized $Agrobacterium$ $tumefaciens$ as a vector to integrate the following specific genes into the rice nuclear genome:
The insertion of the $psy$ and $crtI$ genes successfully bridges the biochemical gap in the rice endosperm. The pathway proceeds as follows:
1. The naturally occurring substrate Geranylgeranyl diphosphate (GGPP) is converted into Phytoene via the introduced $psy$ gene.
2. Phytoene is then converted into Lycopene via the introduced bacterial $crtI$ gene (which performs multiple desaturation steps that normally require two separate enzymes in plants).
3. Finally, the endogenous (naturally present) rice enzyme lycopene $\beta$-cyclase converts Lycopene into $\beta$-carotene.
Once consumed, the human digestive system cleaves the $\beta$-carotene molecule to produce active Vitamin A (Retinol) [By the enzymatic action of $\beta$-carotene 15,15'-monooxygenase]. Golden Rice is designed as a biofortified crop, intended as an accessible public health intervention for developing nations to eradicate preventable childhood blindness and nutritional deficiencies.
Final Solution: Golden Rice is a genetically engineered (transgenic) strain of rice ($Oryza$ $sativa$) that has been fortified with the $psy$ and $crtI$ genes to produce $\beta$-carotene (provitamin A) in its endosperm. It was explicitly created as a biofortified food source to combat systemic Vitamin A deficiency in populations dependent on rice-based diets.
Solution:
In plant tissue culture and agricultural biotechnology, the biological tissue universally recognized as the best suited for generating virus-free plants is the meristem, specifically the apical meristem and the axillary meristem.
Meristems are regions of undifferentiated, actively dividing cells found at the growing tips of roots and shoots. Even if a plant is systemically infected with a virus, these localized terminal regions remain virtually devoid of viral particles.
The exclusion of viruses from the meristematic dome is not due to a single factor, but rather a synergistic combination of anatomical, physiological, and biochemical barriers. [Per the principles of plant pathology and cellular dynamics, the following mechanisms explain this phenomenon]:
The following diagram geometrically illustrates the shoot apex, highlighting the spatial separation between the meristematic dome and the terminating vascular tissues.
To exploit this biological loophole, scientists employ meristem culture (a specialized form of tissue culture). The procedure follows a distinct logical sequence:
Historically, this technique has successfully salvaged economically critical crops such as bananas, sugarcane, and potatoes from devastating viral epidemics.
Final Solution: The apical and axillary meristems are the best-suited parts of the plant for making virus-free plants. This is because meristematic tissues are highly active in cell division (outpacing viral replication rates), lack differentiated vascular connections (phloem) which viruses use for transport, and possess high auxin concentrations and metabolic activity that inhibit viral establishment. Thus, through meristem culture, completely healthy plants can be regenerated from infected parent plants.
Solution:
Gene therapy is a therapeutic technique that involves the insertion, alteration, or removal of genes within an individual's cells and biological tissues to treat or prevent genetic disorders. The core objective is to correct the underlying genetic defect by delivering a functional gene to replace a non-functional or mutated allele, thereby restoring the synthesis of a specific protein or enzyme essential for physiological homeostasis.
ADA deficiency is a hereditary autosomal recessive disorder caused by a deletion in the gene encoding the enzyme adenosine deaminase. This enzyme is critical for the immune system, specifically for the maturation and function of T-lymphocytes. Absence of ADA leads to the accumulation of deoxyadenosine, which is toxic to lymphocytes, resulting in Severe Combined Immunodeficiency (SCID).
The standard approach for treating ADA deficiency involves an ex-vivo method:
Because the lymphocytes have a finite lifespan, the patient requires periodic re-infusion of these genetically engineered cells. To achieve a permanent cure, the genetic modification must be performed on hematopoietic stem cells (HSCs) during the early embryonic or fetal stages, which allows for the production of healthy lymphocytes throughout the patient's life.
| Method | Mechanism | Permanence |
|---|---|---|
| Enzyme Replacement Therapy | Regular injection of functional ADA | Temporary |
| Bone Marrow Transplantation | Replacement of patient's marrow | Permanent (if successful) |
| Gene Therapy (HSCs) | Integration of gene into germline/stem cells | Permanent |
Final Solution: Gene therapy for ADA deficiency is the process of introducing a functional copy of the ADA gene into a patient's T-lymphocytes via a viral vector, thereby restoring immune function. While ex-vivo somatic gene therapy provides temporary relief, integrating the transgene into hematopoietic stem cells offers the potential for a permanent, life-long cure.
Solution:
To propose a biotechnological method for removing oil from seeds, we must first analyze the chemical nature and biosynthetic pathway of seed oils. Oils stored in seeds are predominantly composed of Triacylglycerols (TAGs). Chemically, a TAG molecule consists of a glycerol backbone esterified to three fatty acid chains.
The biosynthesis of TAGs occurs in the endoplasmic reticulum (ER) of the plant cell via the Kennedy Pathway. The final, rate-limiting step in this pathway is the acylation of diacylglycerol (DAG) using a fatty acyl-CoA, which is catalyzed by the enzyme Diacylglycerol acyltransferase (DGAT). Because this step commits the metabolic flux strictly toward oil accumulation, the $DGAT$ gene is the optimal target for genetic intervention.
Based on principles of recombinant DNA (rDNA) technology, we can prevent the synthesis of oil by silencing the gene responsible for its production. The most precise and efficient method to achieve this in plants is Post-Transcriptional Gene Silencing (PTGS) via RNA interference (RNAi) or Antisense RNA technology. By introducing a recombinant construct that silences the $DGAT$ gene, the plant will fail to synthesize the specific mRNA required to produce the DGAT enzyme, thereby halting oil production.
Step 1: Isolation of the Target Gene Sequence
The specific nucleotide sequence of the $DGAT$ gene (or another critical enzyme like Acetyl-CoA carboxylase) is identified and isolated from the plant's genome. We only require a partial sequence (an exon fragment) to act as the silencing trigger.
Step 2: Construction of the Recombinant RNAi Vector
Using restriction endonucleases and DNA ligase, the $DGAT$ gene fragment is cloned into a specialized binary vector (e.g., a Ti-plasmid) in an inverted repeat orientation, separated by a spacer or intron. This construct is placed under the control of a seed-specific promoter (e.g., Napin or Oleosin promoter) to ensure that the gene silencing only occurs in the seeds, preventing lethal metabolic disruptions in the rest of the plant [Per the principles of targeted gene expression].
Step 3: Agrobacterium-Mediated Transformation
The recombinant plasmid is introduced into Agrobacterium tumefaciens, a natural plant pathogen that transfers its T-DNA into the plant genome. The plant tissues are infected with this recombinant Agrobacterium, resulting in the integration of the RNAi construct into the plant's nuclear genome.
Step 4: Cellular Mechanism of Silencing (Transcription and Cleavage)
The following diagram illustrates the intracellular mechanism by which the recombinant dsRNA construct neutralizes the target mRNA.
By knocking down the expression of $DGAT$ through RNA interference, the diacylglycerol intermediate cannot be converted into triacylglycerols. This disrupts the chemistry of oil formation. The unused intermediates are re-routed via alternative biochemical pathways, often resulting in seeds with elevated carbohydrate or protein contents, but effectively removing the hydrocarbon (oil) fraction.
Final Solution: Yes, oil can be removed from seeds by utilizing RNA interference (RNAi) or Antisense technology to silence specific genes encoding key lipogenic enzymes, such as Diacylglycerol acyltransferase (DGAT), effectively halting the final biochemical step of triacylglycerol (hydrocarbon) synthesis without killing the plant.
Solution:
Proteins and peptides hold immense therapeutic potential due to their high specificity and efficacy (e.g., insulin, growth hormones, monoclonal antibodies). However, the standard route of administration is parenteral (intravenous or subcutaneous injections) because the oral route presents severe physiological and biophysical barriers. Developing an orally active protein pharmaceutical requires advanced biochemical engineering to protect the macromolecule during its transit through the gastrointestinal (GI) tract and ensure its systemic absorption.
The human GI tract is evolutionarily designed to break down dietary proteins into single amino acids or di/tripeptides for absorption. Therefore, when a protein pharmaceutical is administered orally, it faces three major hurdles:
To overcome these barriers, biotechnologists and pharmacologists employ a combination of formulation and structural modifications. The primary strategies are detailed below:
The protein is packaged inside protective micro- or nano-carriers. Common carriers include liposomes, Solid Lipid Nanoparticles (SLNs), and polymeric nanoparticles (e.g., PLGA, Chitosan). These carriers act as physical shields against gastric acid and proteases. Chitosan, a positively charged polymer, is particularly useful as it is mucoadhesive, binding to the negatively charged intestinal mucosa, thereby increasing the residence time and local concentration of the drug for absorption.
The protein capsules or tablets are coated with pH-sensitive polymers (like Eudragit). These polymers are completely insoluble in the highly acidic $pH$ of the stomach but dissolve rapidly in the slightly alkaline $pH$ ($pH \approx 6.0 - 7.4$) of the small intestine, releasing the protein drug exactly where absorption is optimal.
Formulations often include biochemical adjuvants:
Covalently attaching Polyethylene Glycol (PEG) chains to the protein surface (PEGylation) creates a steric hydration shield. This masks the protein from proteolytic enzymes and immune cells, drastically increasing its half-life and stability without eliminating its biological activity.
Using recombinant DNA technology, the gene coding for the therapeutic protein is inserted into the chloroplast genome of edible plants (e.g., tomatoes, lettuce). When consumed, the rigid plant cell wall composed of cellulose acts as a natural biological capsule. It resists gastric digestion but is slowly degraded by commensal microbes in the gut, releasing the therapeutic protein into the intestinal lymphoid tissues (GALT).
The following technical schematic illustrates the differential fate of an unprotected protein versus a nano-encapsulated protein navigating the GI tract.
| Physiological Barrier | Biophysical Consequence | Biotechnological Strategy |
|---|---|---|
| Gastric Acid ($pH \approx 1.5$) | Denaturation of protein tertiary & quaternary structure | Enteric coatings, pH-sensitive hydrogels, Bioencapsulation |
| GI Proteases (Pepsin, Trypsin) | Hydrolysis and cleavage of peptide bonds | Co-administration of Protease Inhibitors, PEGylation, Liposomes |
| Intestinal Epithelium | High $M_w$ & hydrophilicity prevent paracellular/transcellular diffusion | Permeation enhancers (surfactants), Mucoadhesive nanoparticles (Chitosan) |
Final Solution: Making an orally active protein pharmaceutical requires encapsulating the protein within advanced delivery systems (like liposomes, enteric-coated nanoparticles, or transgenic plant cell walls) to bypass the major problems of acidic denaturation and enzymatic digestion in the gastrointestinal tract, while co-administering permeation enhancers to facilitate systemic absorption across the intestinal epithelium.
Solution:
The human gene encoding the growth hormone ($hGH$) is isolated from human genomic DNA or synthesized via Reverse Transcriptase ($RT-PCR$) to obtain complementary DNA ($cDNA$), ensuring no introns are present. The gene is flanked with specific restriction sites (e.g., $EcoRI$) using PCR primers.
A plasmid vector (e.g., $pBR322$) is isolated from E. coli. Both the human $hGH$ gene and the plasmid are digested with the same restriction endonuclease. [Per the mechanism of Restriction Fragment Length Polymorphism], this creates complementary sticky ends. The gene is then inserted into the plasmid using the enzyme DNA Ligase to form Recombinant DNA ($rDNA$).
The $rDNA$ is introduced into the host E. coli cells via transformation (using chemical methods like $CaCl_2$ treatment and heat shock at $42^\circ C$). The host cells are then grown on a selective medium containing antibiotics (e.g., Ampicillin) to identify transformants [By the Principle of Selectable Markers].
The transformed E. coli is cultured in a bioreactor under optimized conditions ($pH$, temperature, aeration). The host machinery transcribes and translates the human gene to produce the recombinant growth hormone. The protein is then extracted and purified through downstream processing techniques.
| Phase | Mechanism |
|---|---|
| Cleavage | Restriction Endonuclease digestion of $DNA$ and Vector |
| Ligation | $DNA$ Ligase joins recombinant fragments |
| Amplification | Bacterial binary fission |
| Recovery | Downstream purification of Growth Hormone |
Final Solution: The human growth hormone gene is isolated as cDNA, ligated into a bacterial plasmid vector using DNA ligase, transformed into E. coli via heat-shock, and the resulting recombinant protein is synthesized by the bacterial cell machinery and recovered through industrial downstream processing.